Navigation Links
CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires
Date:3/8/2011

MISSISSAUGA, Ontario, March 8, 2011 /PRNewswire/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH) announced today that it is making available to its common stockholders and Series 2 Class B common stockholders a "Stockholder Questionnaire," which the Company hopes will assist it in obtaining an accurate share count of the Company's shares currently held in "street name" through brokers, banks or other nominees.

If you have not received the Stockholder Questionnaires via mail, you can download copies of the questionnaires from the "Investor Relations" section of the Company's website (www.cardiogenics.com). We urge all stockholders to take the time to complete and return the applicable questionnaire to the Company as soon as possible. The questionnaires contain the mailing address, fax number and e-mail address, which can be used by stockholders for returning their completed questionnaires.

Any inquiries regarding the questionnaires can be directed to Creative Capital and Trading, Inc., which is assisting the Company in this matter:

Creative Capital and Trading, Inc.

Attention: Tony Forte – Tel: 732-751-1947 or

Jeff Goss – Tel: 732-556-6924

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com.

Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE CardioGenics Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioGenics Granted Patent for Core Technology of its QL Careā„¢ Analyzer
2. CardioGenics to File for 510K Clearance With the United States Food and Drug Administration by Q4 2011
3. CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS
4. CardioGenics Raises $1.9 Million in Private Placement
5. CardioGenics Featured on Cover of Medical Device & Diagnostic Industry Magazine
6. Zacks Rates CardioGenics Outperform With Six-Month Target of $1.22
7. CardioGenics Featured on Canadas Business News Network
8. CardioGenics Holdings Inc. Receives New Ticker Symbol
9. CardioGenics Selects Clinical Test Sites for Its High Speed Portable Blood Analyzer
10. New Corporate Profile Posted On CardioGenics Website
11. CardioGenics Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... The Rebound mobile app is poised to become ... tide of prescription drug addiction. The app empowers users to ... stepping down their dosage in a safe, controlled manner while ... the first 100,000 people to sign up will enjoy 3 ... ...
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... R.I. , Sept. 25, 2017  EpiVax, ... assessment, vaccine design, and immune-engineering today announced the ... on the development of personalized therapeutic cancer vaccines. ... has provided exclusive access to enabling technologies to ... Eng., MBA will lead EpiVax Oncology as Chief ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) of ... collection of specialty vendors and unique items from across the nation, this holiday-themed event ... wellness services offered by the VNA. The boutique will be open Saturday, November ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a leader in ... awarded a contract by the Center for Medicare and Medicaid Services (CMS). The ... enterprise use of Agile methodologies in a consistent and high value manner across ...
(Date:10/12/2017)... , ... October 12, 2017 , ... Planet Fitness, one ... U.S., announced today its plans to open a flagship location in Covington, LA at ... former Rooms To Go store next to Office Depot in the Holiday Square shopping ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
Breaking Medicine News(10 mins):